Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.

ABSTRACT:

Opinion statement

Limited-stage small cell lung cancer (LS-SCLC) is a potentially curable disease. However, most patients develop disease relapse shortly after definitive treatment. The landmark trials IMpower133 and CASPIAN demonstrated a survival benefit with the addition of immunotherapy to first-line platinum/etoposide for extensive-stage small cell lung cancer. Therefore, it is critical to determine whether advancements in overall survival with immunotherapy can be translated earlier into the treatment paradigm for LS-SCLC. Decades of robust preclinical research into the synergism of radiation therapy and immunotherapy set the stage for the combination of these treatment modalities. Recently published data suggests tolerability of single agent immunotherapy concurrent with che

SUBMITTER: Schlick B 

PROVIDER: S-EPMC9345799 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature